Brevan Howard Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Brevan Howard Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-135,621	Closed	-$4.54M	–	2542
2026 Q1	$4.54M	Sell	135,621 -12,179	-8%	-$477K	0.04%	263
2025 Q4	$6.84M	Buy	147,800 +133,540	+936%	+$7.32M	0.07%	172
2025 Q3	$964K	Buy	+14,260	New	+$1.06M	﹤0.01%	912

Brevan Howard Capital Management's SLNO Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 135,621 shares — an estimated $4.54M sold.

Brevan Howard Capital Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $6.84M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Brevan Howard Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 135,621 Soleno Therapeutics shares in Q2 2026, an estimated $4.54M.
Brevan Howard Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Brevan Howard Capital Management's Soleno Therapeutics position peaked at $6.84M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.